NL-OMON37803已完成不适用
Prospective assessment of mumps virus transmission - Mumps virus transmission
RIVM0 个研究点目标入组 645 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 645
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 12 至 99(—)
入选标准
- •Transmission part:
- •* Elegibilty of the contacts of an index case depends on the index case. The contacts of an index case are only eligible for participation when the index case has a laboratory confirmed mumps virus infection and when the index case belongs to a suitable social network.
- •* The suitability of the network will be assessed by the research team. A suitable network is one with a high chance of mumps transmission occurring. This will depend on the age and residential situation of the network. The research team will use descriptive epidemiological information from mumps transmission networks that occurred in 2010 and 2011.
- •* >= 16 years of age
- •* Inclusion of first ring contacts should be within 10 days of the first symptoms of mumps disease of the index case;Cellular immunity part:
- •A mumps case is eligible for participation in the cellular immunity study as case when mumps virus infection has been laboratory confirmed, and when he/she is >=18 yrs of age.
- •A control for the cellular immunity study is a person who has no evidence of a recent mumps infections, e.g. contacts from the transmission study with a negative clinical history and absence of a serological response, has been vaccinated against mumps in the past, and he/she is >=18 yrs of age.
排除标准
- •Transmission part:
- •- having mumps at the time of inclusion, or ever have had mumps in the past.
- •Cellular immunity:
- •- be or have been under immunosuppressive medical treatment, like cytostatics and prednisolons that might interfere with the results of the study (within the previous 3 months)
- •- have any known primary or secondary immunodeficiency, or bleeding disorder
研究者
相似试验
已完成
不适用
Mumps virus transmission in vaccinated populations,WP 2: short-term and long-term complications of mumps-associated orchitis in vaccinated men * a prospective multicenter cohort trialorchitismumpsNL-OMON36170Academisch Medisch Centrum30
已完成
1 期
A Phase I, Safety Study of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese ChildrenMumpsNCT01712906Institute of Medical Biology, Chinese Academy of Medical Sciences300
进行中(未招募)
2 期
Phase II/III of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Healthy Children Aged 5-11Epidemic Parotitis, MumpsNCT04591405Institute of Medical Biology, Chinese Academy of Medical Sciences11,999
进行中(未招募)
2 期
Phase II of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese InfantsEpidemic Parotitis,MumpsNCT03133923Institute of Medical Biology, Chinese Academy of Medical Sciences1,080
已完成
不适用
Investigation of incidence of measles, mumps and rubella in patients with inflammatory bowel diseaseulcerative colitis, Crohn's diseaseJPRN-UMIN000005443Gastroenterology and Hepatology Tokyo Medicaland Dental University100
